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ABSTRACT
The first study was conducted to determine if aminophylline cream application to the
waist will reduce waist circumference compared to a control. Topical fat reduction from the
thigh in women has been demonstrated, but local fat reduction in other areas or in men has not.
Fifty men and women were randomized to 0.5% aminophylline cream to the waist twice a day or
to no treatment to the waist. At week 12 there was a significant reduction in BMI from baseline
that was not different between the groups. The reduction in waist circumference was 11 + 1.0
cm in the aminophylline cream group and 5.0 + 0.6 cm in the control group (p<0.001). The
reduction in waist circumference was significant for both sexes, but women lost significantly
more waist girth. The waist-to-hip ratio declined, aminophylline levels were undetectable, and
there were no adverse events.
The second study developed a cost-effective method of breast measurement that will
allow our research team to test the concept of fat redistribution. Breast volume measurements
were compared using the Grossman-Roudner cone, plaster casting, and MRI. Five women with
breast sizes AA, A, B, C, and D had three volume measures repeated three times. For a single
volume measurement, the costs were: $1 for the Grossman-Roudner cone, $20 for the cast, and
$1,400 for the MRI. The relative cost for volume measurements using the cast was 64-189 times
greater, and using the MRI was 373-33,500 greater than the cost of the Grossman-Roudner cone.
The final study used a human fat cell assay to determine the capacity of currently
used mesotherapy solutions to stimulate lipolysis and to determine the effect of combining a
local anesthetic to the solutions. The fold induction of the mesotherapy solutions measured by
glycerol generation was used to determine their capacity to stimulate lipolysis. Isoproterenol
(p<0.002), aminophylline (p<0.00004), and yohimbine (p<0.001) stimulated lipolysis compared
to the buffer. The lipolysis stimulated by melilotus and isoproterenol was enhanced by
viii

aminophylline (p<0.001). Lidocaine inhibited lipolysis when added to aminophylline and
isoproterenol (NS compared to buffer), and when added to aminophylline, isoproterenol, and
yohimbine (p<0.05 compared to control).

ix

CHAPTER 1
INTRODUCTION
Obesity
Obesity is defined by a body mass index (BMI) greater than 30 kg/m2, overweight as a
BMI between 25 and 30 kg/m2, and morbid obesity as a BMI greater than 40 kg/m2 or greater
than 35 kg/m2 in association with obesity-related disease expected to improve with weight loss.
Approximately 66% of the United States population is overweight and over 30% are obese.
Approximately 5% have a BMI greater than 40 kg/m2 (Hedley et al., 2004 and Freedman et al.,
2002). Flegal describes obesity as an "epidemic” which gives the implication that obesity is a
characteristic of entire populations, not just of individuals (1999).
Obesity is defined as a BMI above 30 kg/m2, because, at that level the risk of death is
1.25 to1.5 times higher than lean controls, and the definition of diastolic hypertension above
90mmHg or total cholesterol above 200 mg/dL is defined by similar increases in risk (Bray,
1996). Obesity increases the relative risk of diabetes, hypertension, dyslipidemia, gallbladder
disease, and sleep apnea by more than three fold (WHO, 1997). Morbid obesity, or class III
obesity, has been named so because of the high incidence of serious medical diseases associated
with it. In the morbidly obese, the prevalence of elevated triglycerides and low HDL cholesterol
is 40%, of diabetes or impaired glucose tolerance is 34%, of hypertension is 26%, and of
unemployment is 62% (Greenway, 1996). Studies have shown that for people with a BMI
greater than 40 kg/m2, the increase in the relative risk of death was 2.58 times higher in men and
2 times higher in women in comparison with people whose BMI was between 23.5 and 24.9
kg/m2 (Stevens et al., 1998). Research has concluded that between 112,000 and 325,000 deaths
each year can be accredited to obesity (Allison et al., 1999 and Flegal et al., 2005).
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Not only is obesity a detriment to one’s health, but also a detriment to the economy.
Wolf and Colditz describe the estimated cost of obesity, which is attributed to associated
diseases such as type 2 diabetes mellitus, coronary heart disease, hypertension, gallbladder
disease, osteoarthritis, and breast, endometrial, and colon cancer (1998). The National Health
Interview Survey was used to estimate that obesity cost the United States approximately $100
billion dollars in 1995.
In addition to the numerous health and economic issues of obesity, there is a very
powerful stigma associated with both overweight and obesity. A discrimination and prejudice
has become common towards the overweight and obese (Puhl and Brownell, 2001). In a study
performed by Crandall, parents discriminate against their own overweight children (1995). Thin
siblings received greater financial support from their parents than their own overweight siblings,
regardless of income, education, or family size. In a study performed by Brylinsky and Moore,
children as young as three years old referred to overweight children as ugly, stupid, and mean
(1994). Another study by Latner and Stunkard produced astonishing results (2003). Children
would rather have a friend with a handicap, such as being in a wheelchair, having an amputated
hand, or having a facial deformity rather than having an obese friend.
Obesity Intervention Mechanisms and the Role of Lipolysis
Obesity is caused by an energy imbalance. People who are overweight or obese eat more
calories than they expend. Fat is a dynamic storage depot of body energy. Calories from the
food people eat are stored in the fat during the day and some of that fat is mobilized at night to
meet energy needs until breakfast the next day through lipolysis. Thus, lipolysis is one of the
mechanisms that has promise for intervention in this energy imbalance problem.
Angiogenesis is another mechanism that has the potential to treat energy imbalance.
Inhibitors of angiogenesis reverse obesity in rodent models, and an assay based on human fat
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tissue has been validated for use in screening angiogenesis inhibitors for the treatment of obesity
(Roberts et al., submitted, 2005). Using this assay, gallic acid was discovered to be a plant
ingredient with angiogenic inhibitory properties. A clinical trial of gallic acid for the treatment
of obesity was unsuccessful and subsequent studies demonstrated that gallic acid is not well
absorbed from the gastrointestinal tract (Roberts et al., submitted, 2005).
Although there are many other examples of mechanisms by which one might intervene to
treat obesity, this thesis focuses on lipolysis as a mechanism by which adipose tissue can be
regulated. Lipolysis is defined as the hydrolysis of lipids, or simply the process of dissolving fat.
This happens when one diets and forces his or her body to burn stored fat. During this process
hormone sensitive lipase breaks down fat into glycerol and free fatty acids, which are released
into the bloodstream, where they may be either re-esterified by adipocytes or metabolized (Large
et al., 2004). Thus, lipolysis plays a central role in the regulation of fat mass composed of
human fat cells, or adipocytes. There are two main pathways involved in lipolysis: the betaadrenergic pathway, which is cyclic AMP mediated, and the natriuretic peptide pathway, which
is mediated by cyclic GMP (Robidoux et al., 2004). Recent evidence suggests that the novel
natriuretic peptide system promotes lipolysis only in primate adipocytes.
The classic pathway for lipolysis in fat cells starts with activation of the beta-adrenergic
receptor by beta-agonists via the Gs proteins in adipocytes (Robidoux et al., 2004). This leads to
the activation of adenylate cyclase, which then increases cyclic AMP levels. Elevated cyclic
AMP behaves as a second messenger, which activates hormone sensitive lipase. Hormone
sensitive lipase, the rate-limiting enzyme regulating adipocyte lipolysis, then catalyzes the
hydrolysis of triglycerides and results in the release of glycerol and free fatty acids. This process
causes increased lipolysis. Enzymes called phosphodiesterases hydrolyze cyclic AMP into 5’
AMP, which causes a decrease in lipolysis. Through a series of reactions, catecholamines, such
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as epinephrine and norepinephrine, will either stimulate lipolysis via β-adrenergic receptors or
inhibit lipolysis via α-adrenergic receptors or adenosine receptors in fat cells.
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Figure 1.1. Lipolysis in Human Fat Cells

Nutritional Treatments for Obesity
Since obesity is a result of eating more energy than one expends, restricting calories
through dieting has been the mainstay of obesity treatment along with behavior changes that
reduce calorie intake and encourage activity-associated energy expenditure. Since obesity
increases the risk for cardiovascular disease by two to three-fold, interest has also focused upon
food choices that will further reduce this risk outside the mere restriction of calories. One
example of this approach will be described in some detail. A chocolate covered snack bar
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containing 14 grams of full fat rice bran, 6.25 milligrams thiamine, 125 milligrams ascorbic acid,
6.25 milligrams pyridoxine, 37.5 micrograms cyanocobalamin, 50 units tocopherol, 0.125
milligrams folic acid, 500 milligrams of omega-3 fatty acids and 220 calories was developed and
compared to a placebo bar without vitamins, similar calories and corn starch/corn oil instead of
rice bran/omega-3 fatty acids (Caruso et al., 2005.). This bar was tested to determine its effects
on total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, C-reactive protein, and
homocysteine. Nine of the ten healthy subjects were on no regular medications, the men were
25-45 years old, the women were 25-55 years old, LDL was between 130-190 mg/dl, and
triglycerides were between 150-300 mg/dl. This trial was completed using a randomized doubleblind crossover design with balanced order treatments. Subjects incorporated six bars/day in a
weight maintaining diet. Homocysteine and lipids were drawn twice at the end of each fourweek treatment period and compared by paired t-test. Homocysteine decreased more during the
rice bran bar period than during the placebo period (7.1 vs. 7.8 mcmol/L, p=0.028). Total
cholesterol, LDL, triglycerides and C-reactive protein decreased more and HDL increased more
during the rice bran bar period, but the changes were not statistically significant. This bar for
cardiovascular health decreased serum homocysteine, a recognized cardiovascular risk factor.
Although 6 bars per day may not be a practical method of reducing cardiovascular risk, the study
demonstrates that using foods that function to improve health is a viable approach with scientific
support.
Prescription Treatments for Obesity and Dietary Herbal Supplements
The development of drugs for the treatment of obesity began at the end of the nineteenth
century with the discovery of thyroid hormone (Putnam, 1893). Over the past one hundred
years, obesity drugs have had a disastrous safety record. Amphetamines were associated with
drug abuse, dinitrophenol was associated with death from hyperthermia, and most recently
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fenfluramine was withdrawn from the market due to an association with cardiac valvular
insufficiency (Greenway and Caruso, 2005). In part due to this dismal safety record, the medical
profession has looked to drugs approved for purposes other than obesity that have demonstrated
an acceptable record of safety in chronic therapy. Bupropion, a drug approved for the long-term
treatment of depression has been demonstrated to give weight loss (Anderson et al., 2002).
Looking to drugs that stimulate lipolysis is another mechanistic approach that also deserves
scrutiny. One drug that fits into that category is the lipolytic stimulator, brain natriuretic peptide,
which is an approved treatment for congestive heart failure. It is an expensive protein that is not
orally active, both being obvious drawbacks for use as an obesity treatment.
Dietary herbal supplements, which are technically classified as food, are another potential
source of lipolytic stimulators. Ephedra was a dietary herbal supplement that stimulated the
beta-adrenergic receptor and caused lipolysis, but it was removed from the market for
cardiovascular toxicity. Ephedrine combined with caffeine has been used to treat asthma since
the 1930’s, and it was an approved and successful weight loss drug in Denmark for over a
decade.
In a clinical trial performed in Denmark for approval as an obesity drug, 180 obese
subjects were randomized to placebo, caffeine 200 mg, ephedrine 20 mg, or caffeine and
ephedrine three times a day for six months. The groups on caffeine or ephedrine lost no more
weight than placebo and did not differ from each other, but the group on caffeine with ephedrine
lost significantly more weight than placebo. Another study by the same group illustrated that
caffeine and ephedrine increase resting energy expenditure as part of their mechanism in causing
weight loss. In another study performed by Vukovich et al., 20 mg of ephedra combined with
150 mg of caffeine resulted in an increase in resting energy expenditure, heart rate, and blood
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pressure (2005), but other studies have shown that blood pressure and heart rate return to placebo
levels by eight weeks (Astrup et al., 1992).
Despite its many beneficial effects, ephedra has recently been taken off of the market due
to its negative cardiovascular effects. In a study performed by Haller and Benowitz, 140 reports
of adverse events were reviewed and were considered related to the use of dietary supplements
containing ephedra alkaloids. These 140 reports were selected from all those submitted to the
FDA between June 1, 1997, and March 31, 1999 (2000). Hypertension was the single most
frequent adverse effect (17 reports), followed by palpitations, tachycardia, or both (13); stroke
(10); and seizures (7). Ten events resulted in death, and thirteen events produced permanent
disability, representing twenty-six percent of the definite, probable, and possible cases.
Since dietary herbal supplements for obesity drugs are used for a stigmatized disease,
there is the potential for abuse especially when they are available without a prescription. Thus,
there is a reluctance to treat obesity with a supplement that has the potential for side effects. For
both of these reasons there is a higher standard for the safety of obesity drugs than for other
chronic diseases such as diabetes or hypertension (Greenway and Caruso, 2005). In fact, clinical
trials for approval of obesity drugs are at least twice as long as the trials for diabetes or
hypertension drugs.
There is also an economic challenge that obesity drugs have to face. Most insurance
companies still consider obesity to be a cosmetic concern, and most obesity drug purchases are
entirely covered by the consumer. Although consumers are concerned with their health, they are
more concerned about looking thinner. Society is particularly prejudiced against women with
obesity, and this is reflected in the percentage of women participating in clinical trials for obesity
drugs. The prevalence of obesity is similar in both genders, but 80% of the participants in
clinical trials for obesity drugs are women (Greenway and Caruso, 2005). Therefore, there is a
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great challenge to meet the demand for a drug with a greater safety and efficacy than the present
obesity drugs available.
Cosmetic Treatments for Obesity
Although the focus for medical issues associated with excess body fat is on people with a
BMI over 30, even overweight people experience discrimination. Thus, the quality of life for the
obese and overweight is impaired in our society. Treatments that allow safe body contouring and
spot fat reduction have the potential to improve the quality of life experienced by the overweight
and obese. Furthermore, safe medical treatments addressing cosmetic fat reduction may also
reduce the demand for plastic surgical intervention, saving lives by reducing the need for more
invasive treatments.
Fat Reduction
Fat is distributed into two different patterns, gynoid, or pear shaped, and android, or apple
shaped. A major cosmetic concern for women with a gynoid fat distribution is the size of their
thighs, while for women and men with an android fat distribution; it is the size of their waist.
The influence of endogenous stimulators and inhibitors of the lipolytic process determine the
threshold for lipolysis at the fat cell in the human body. The relative lipolytic thresholds of the
body’s fat cells, therefore, determine a person’s fat distribution. Since obesity presents a real
stigma for society, cosmetic alternatives have been created to treat the problem. Lipolytic
stimulators have been injected locally or transdermally using ointments or creams (Greenway et
al., 1995). Aminophylline 0.5% cream has been shown to reduce thigh girth compared to a
vehicle control (Greenway et al., 1995). Aminophylline, two theophylline molecules joined by
ethylenediamine, inhibits the breakdown of cyclic-AMP in the fat cell amplifying the lipolytic
signal and lowering the lipolytic threshold. This study performed by Greenway et al. illustrates
that aminophylline, a lipolytic stimulator, results in fat loss from a particular area when applied
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locally to the thighs (1995). Aminophylline cream offers a safe and effective method for
cosmetic local fat reduction from the thigh, and it is less invasive than cosmetic surgery.
Topical fat reduction from the thigh in women using aminophylline cream has been
demonstrated, but the local fat reduction in other body areas or in men by lowering the lipolytic
threshold with aminophylline cream has not. Since thigh fat reduction with aminophylline cream
occurs due to a reduction in the local lipolytic threshold, the same principle should apply to other
local body areas. Therefore, the waistline is another problematic area that will be tested to
determine if aminophylline cream will reduce waist circumference compared to a control.
Fat Redistribution
When weight is stable, fat is stored throughout the day by food intake and used at night to
uphold a balance in energy. Fat is distributed based on the sensitivity of the receptors located on
the fat cells for lipolysis. Lowering the lipolytic threshold locally in one particular area and
blocking lipolysis in another should result in fat redistribution. Pear-shaped women are often not
only concerned about the amount and appearance of the fat on their hips and thighs, but they
often also want larger breasts. Therefore, if the lipolytic threshold of the breast fat was raised
while mobilizing fat from the thighs, one could, in theory, shift fat from the thighs to the breasts.
This has more than theoretical interest, since women with these cosmetic concerns are now
resorting to invasive procedures like liposuction and breast implants. If a combination of creams
applied to the thighs and breasts were effective in shifting fat from one area to the other, this
would be an alternative cosmetic solution, one that would be non-invasive and reversible with
discontinuation of the creams.
Nicotinic acid is a vitamin that has been used in doses of two to five grams per day orally
to treat elevations in cholesterol and triglycerides. Nicotinic acid reduces serum triglycerides by
blocking lipolysis at the fat cell through inhibition of hormone sensitive lipase. This anti-
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lipolytic effect involves the inhibition of cyclic adenosine monophosphate through an inhibitory
G-protein acting upon adenylyl cyclase (Tunaru et al., 2003). A two gram oral dose of nicotinic
acid gives a serum concentration of 10 -4 Molar while the dose needed to maximally inhibit
lipolysis in vitro is 10 –5 Molar (Niaspan®, 2003 and Green et al., 1991). Therefore, injecting
10 –5 Molar nicotinic acid into the breast would expose the fat cells in that area to levels only one
tenth of the concentrations present in the blood stream during routine treatment of
hypertriglyceridemia with nicotinic acid.
Utilizing the concept of “shifting fat”, a study was performed to test the concept of fat
redistribution since local fat reduction was effective. One woman used 0.5% aminophylline
cream to both thighs and nicotinic acid cream to one breast twice a day for four weeks. There
appeared to be a slight increase in the size of the treated breast, but the results of this pilot trial
were in question. The breast measurements were done using water displacement. This proved to
be a difficult method to use and one with irreproducible results since breasts float. It was
concluded from this one patient pilot study that the development of a reproducible measure of
breast volume was needed to prove the validity of the concept of shifting fat between body
depots.
Mesotherapy
Mesotherapy is the process of injecting small amounts of drugs in the subcutaneous and
intradermal tissues of the skin, the mesoderm, and was introduced by Dr. Michael Pistor in 1952
as a treatment for asthma (Pistor, 1964). Mesotherapy first began in France and the French
medical schools actually include it in their program of study. Mesotherapy has recently been
gaining in popularity in the United States. The primary application in the United States has been
to induce lipolysis for local fat reduction and to reduce the appearance of cellulite on the
buttocks and thighs of many women.
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Isoproterenol, aminophylline, yohimbine, and melilotus are common ingredients used
empirically in mesotherapy, alone and in combination. The use of mesotherapy solutions to
induce local lipolysis is primarily based on empirical observations and long-tem clinical use,
including the use of local anesthetics like lidocaine or procaine in these mesotherapy solutions.
Therefore, it is important to determine the capacity of various mesotherapy compounds and
mixtures to stimulate lipolysis as well as to determine the effect of combining a local anesthetic
on lipolysis included in mesotherapy combinations.
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CHAPTER 2
∗

TOPICAL FAT REDUCTION FROM THE WAIST
Background

The influence of endogenous stimulators and inhibitors of the lipolytic process determine
the threshold for lipolysis at the fat cell in the human body. The relative lipolytic thresholds of
the body’s fat cells, therefore, determine a person’s fat distribution. The greater abundance of
lipolytically inhibitory alpha-2-adrenergic receptors on the thigh fat cells of women under the
influence of estrogen is felt to be responsible for the characteristic lower body fat distribution
typical for women (Lafontan et al., 1979). Fat is a dynamic storage organ. When weight is
stable, fat is stored in fat cells during the day as people eat and used during the night to sustain
the body until breakfast the next morning. Fat is quantitatively mobilized from the individual fat
cells in proportion to the individual lipolytic thresholds of the regional fat deposits. It is,
therefore, logical to assume that lowering the lipolytic threshold in a local fat deposit will cause
its fat stores to be preferentially depleted through the dynamic process of body lipid turnover.
There are several methods to lower the local lipolytic threshold at the fat cell. One can
inject a lipolytic stimulator locally or deliver the lipolytic stimulator transdermally using
ointments or creams (Greenway et al., 1995). Aminophylline 0.5% cream has been shown to
reduce thigh girth compared to a vehicle control (Greenway et al., 1995). Aminophylline, two
theophylline molecules joined by ethylenediamine, inhibits the breakdown of cyclic-AMP in the
fat cell amplifying the lipolytic signal and lowering the lipolytic threshold.
Fat is distributed in two different patterns – “gynoid” and “android”. A major cosmetic
concern for women with a gynoid fat distribution is the size of their thighs, while for women and
men with an android fat distribution; it is the size of their waist. Since thigh fat reduction with
∗

Reprinted by permission of Diabetes, Obesity and Metabolism.
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aminophylline cream occurs due to a reduction in the local lipolytic threshold, the same principle
should apply to other local body areas. This study is designed to test the hypothesis that 0.5%
aminophylline cream applied to the waist will cause preferential fat loss from that location.
Methods
Fifty overweight and obese men and women with a BMI > 27 kg/m2, between the ages of
21 and 65 years of age and with an android fat distribution characterized by a waist to hip ratio >
0.80 in women or > 1.0 in men were included in this study. Subjects using aminophylline,
theophylline, or having a known allergy to either was excluded, as were subjects with
uncontrolled hypertension.
At baseline all subjects were instructed to follow a balanced 1200 kcal/d diet and
encouraged to follow a walking program throughout the 12-week study. The subjects gave
dietary histories of eating 1800-2200 kcal/d. Although we suspect that they may have been
eating more, we chose a 1200 kcal/d diet since it is generally recognized as safe in a weight loss
program and is a 600-1000 kcal/d deficit from their stated caloric intakes. The subjects were
randomized with blocking for gender into two groups of 25 subjects, one receiving a 0.5%
aminophylline water-based cream, and the other receiving no topical treatment served as a
control. Randomization procedures were performed by a person who did not see the participants,
using a random number table and blocking for gender. All participants in the 0.5%
aminophylline cream group were instructed to rub 15 cc of the cream on their waist twice a day
for the duration of the 12-week trial. For purposes of cream application, the waist was defined as
the area from the lower rib margins to the iliac crest. Subjects were seen every 2 weeks,
encouraged to follow their diet, encouraged to continue their walking program, encouraged to
apply the cream twice daily, blood pressure and pulse were measured, the waist skin was
inspected, and they were asked if they had experienced any adverse events. Each month, blood
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was drawn to measure the theophylline level. The theophylline was measured at 6 and 24 hours
after the cream application. The timing of levels was based on the oral absorption characteristics
of aminophylline, and the standard theophylline assay used in the local clinical laboratory was
employed for measurement. The BMI, waist circumference and hip circumference were remeasured at the end of the 12-week study. The BMI, waist circumference and the waist to hip
ratio were analyzed by t-test.
Results
Twenty females and 5 males were in both groups, and groups were well matched for
body mass index at baseline, 28.2 kg/m2 + 1.0 (SEM) vs. 28.5 + 1.0 kg/m2 (p = NS), range 27.135 kg/m2, for the aminophylline cream and the control groups, respectively. The average waist
circumference was 97.8 + 2.4 cm, 93.8 + 1.5 cm in women (range 80-105 cm) and 115 + 3.6 cm
in men (98-130 cm) confirming that the study population had an android fat distribution. The
waist circumference of the two groups was not different at baseline. The average waist to hip
ratio was 0.94 + 0.03, 0.97 + 0.001 in women (range 0.94 – 0.99) and 1.34 + 0.17 (range 1.151.62). All 50 subjects completed the study.
At week 12, the BMI in the aminophylline cream group was 26.1 + 1.0 kg/m2 and 26.2 +
1.0 kg/m2 in the control group, a significant reduction in BMI from baseline of 2 kg/m2 in both
groups. The reduction in waist circumference was 11 + 1.0 cm in the aminophylline cream
group and 5.0 + 0.6 cm in the control group (p<0.001). The reduction in waist circumference
was significant for both women (11.6 + 0.6 cm in the aminophylline group and 5.6 + 0.6 cm in
the control group) and men (9.4 + 0.7 cm in the aminophylline group and 4.7 + 0.6 cm in the
control group) (p<0.001). Women treated with 0.5% aminophylline cream lost more girth (11.6
+ 0.6 cm vs. 9.4 + 0.7 cm) than the men (p<0.001), see Table 2.1. The waist to hip ratio declined
more in the group treated with 0.5% aminophylline cream than the control group (0.08 + 0.03 vs.
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0.02 + 0.03, p<0.01). The waist to hip ratio in women declined more in the group treated with
0.5% aminophylline cream than the control group (0.12 + 0.001 vs. 0.05 + 0.001, p<0.001), and
the waist to hip ratio in men declined more in the group treated with 0.5% aminophylline cream
than the control group, but this difference was not statistically significant (0.2 + 0.06 vs. 0.09 +
0.07, NS), see Table 2.2. The lack of difference in weight loss between the two groups and the
difference in waist circumference suggests a cosmetic change in fat distribution. All monthly
aminophylline levels were undetectable. There were no adverse events or allergic reactions to
the cream. Blood pressure and pulse remained in the normal range throughout the study.

Table 2.1. Changes in Waist Circumference (cm) from Baseline in the Two Groups
and Separately for Men and Women
______________________________________________________________________
Group

Waist

Male Waist

Female Waist

______________________________________________________________________
0.5% aminophylline (cm)

-11 + 1.0a

-9.4 + 0.7c

-11.6 + 0.6a

Control (cm)

-5.0 + 0.6b

-4.7 + 0.8b

-5.6 + 0.6b

______________________________________________________________________
Table 2.1 shows the changes in waist circumference (cm) from baseline in the two groups and
separately for men and women. Different superscripts show values that are significantly
different from one another (p<0.001).
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Table 2.2. Changes in Waist to Hip Ratio (cm) from Baseline in the Two Groups and
Separately for Men and Women
________________________________________________________________________
Group
Waist/Hip
Male Waist/Hip
Female Waist/Hip
________________________________________________________________________
0.5% aminophylline (cm)

-0.08 + 0.03e -0.2 + 0.06

-0.12 + 0.001g

Control (cm)

-0.02 + 0.03f -0.09 + 0.07

-0.05 + 0.001h

________________________________________________________________________

Table 2.2 shows the changes in waist to hip ratio from baseline in the two groups and separately
for men and women. Different superscripts show values that are significantly different from one
another (p<0.001).
Discussion
This trial demonstrates that reducing the local lipolytic threshold with topical
aminophylline cream results in a reduction of waist circumference in both men and women.
Local girth reduction of the waist in android body types is consistent with the principle that
lowering the local lipolytic threshold causes fat reduction in the area of application. Thus, one
can extend the principle of local fat reduction with aminophylline cream to both genders and to a
body area different from the thigh. This difference in waist circumference with a similar weight
loss in the two groups suggests a cosmetic redistribution of body fat.
In developing aminophylline cream it was appreciated that aminophylline, two
theophylline molecules joined by ethylenediamine, is a skin sensitizer and chemically reactive
due to the ethylenediamine it contains. A standard cream base turned yellow from a chemical
reaction with aminophylline. This yellow cream was ineffective and caused rashes in some
subjects.
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Using a specially formulated cream base to stabilize the aminophylline, the safety and
efficacy of local thigh fat reduction was demonstrated (Greenway et al., 1995). The same cream
base was used in this study. Not only was the aminophylline cream effective for reduction of
waist circumference in this study, but also it was safe. The undetectable aminophylline levels
confirmed that the cream was acting locally, and there were no rashes or adverse events during
the trial.
Although a placebo cream was not used in the control group, the two groups were well
matched at baseline, and the BMI loss was similar in both groups. The purpose of the 1200
kcal/d weight loss diet was twofold: 1) to address the subject’s overweight problem, and 2) to
lower the lipolytic threshold through negative caloric balance.
The waist to hip ratio has been used as a surrogate measure of insulin resistance due to its
correlation with visceral fat (Peiris et al., 1987 and Peiris et al., 1988). Visceral fat correlates
with insulin resistance (Sironi et al, 2004). Since the local fat reduction reduced the
subcutaneous abdominal fat, it presumably does not reduce insulin resistance despite the
reduction in the waist to hip ratio. The change in waist to hip ratio in this study is confirmation
that the fat shifted away from the waist.
The most common cosmetic concern for those with a gynoid fat distribution is the size of
their thighs, and for those with the android fat distribution is the size of their waist. This study
demonstrates that fat can be preferentially and safely mobilized from the waist during weight
loss in those with an android fat distribution. Psychosocial benefit may derive from the cosmetic
changes, but these were not addressed in this study. Aminophylline cream offers a safe and
effective method for cosmetic local fat reduction from the waist, and it is less invasive than
cosmetic surgical procedures.
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CHAPTER 3
∗

THE COST-EFFECTIVENESS OF THREE DIFFERENT MEASURES OF BREAST
VOLUME
Introduction
Our clinical research program is preparing to test topically applied compounds to increase

breast size as a medical substitute for surgical breast augmentation surgery. In order to evaluate
the efficacy of breast augmentation creams, one needs a validated and reproducible method of
measuring breast size. Since women with small breasts most frequently request breast
augmentation, any measuring procedure must be capable of measuring very small breast sizes.
Previously used breast measuring systems have focused upon breast sizes near the mean, and the
applicability of these measurement systems to small breasts is not known.
Breast sizing for bra fitting has used the difference in chest circumference measured at
the ribcage near the submammary crease and the circumference at the nipple level. Although the
precision of this measure may be adequate as a starting point to fit bras in a women’s underwear
shop, it is too imprecise to use as a scientific outcome measure of breast size, especially when
the breasts are ptotic (Pechter, 1998).
The Grossman-Roudner Breast Measuring Device is a circle of flexible plastic with a cut
to the center along a radius line. This circle, which can be formed into a cone-shaped device,
comes in three diameters and is appropriate for measuring breasts with volumes of 125-200 cc,
200-300 cc, and 300-425 cc, which roughly correspond to A, B and C size breasts. The circle is
overlapped upon itself to make a cone, and the cone is shaped around the breast with the volume
of the cone determined at the overlap of the cut radius on the surface of the cone. The
Grossman-Roudner Breast Measuring Device was formerly available from Cox-Uphoff
International, in Santa Barbara, California.
∗

Reprinted by permission of Aesthetic Plastic Surgery.
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The casting method involves exerting gentle pressure on the breast tissue. One can
define the edges of the glandular tissue. The edges of the breast tissue can be marked by
applying kite string to the chest wall with glue. Making a cast of the breast tissue and measuring
the volume of the cast may be a more accurate method of measuring breast size than the
Grossman-Roudner cone, since breasts are not truly conical in shape. MRI is a method that gives
the greatest anatomical detail, and similar imaging techniques have been used to measure
anatomic volumes such as intraabdominal fat ( Bulstrode et al., 2001). Magnetic resonance
imaging has been used to predict survival in individuals with cervical cancer by measuring the
tumor volume (Soutter et al., 2004). Therefore, we thought that measuring breast volume using
calculations from a magnetic resonance imaging (MRI) scan would be the most accurate and
reproducible method, yet also the most costly.
This study proposes to compare the volume of the breast measured from the GrossmanRoudner Breast Measuring Device, the volume of a breast cast, and the volume of the breast
measured from an MRI scan. These methods will be compared to determine the reproducibility
of the measures over a range of breast sizes. The variability measure will be used to determine
the number of subjects needed to detect a given difference in breast volume. The number of
subjects multiplied by the cost of the test will be used to determine the relative cost-effectiveness
of the three methods.
Methods
Five women who had no breast surgery were included in this study. Each woman
represented one of the following bra cup sizes: AA, A, B, C, and D. Each woman had three
separate breast volume measurements using the following three methods.
1. Grossman-Roudner Breast Measuring Device (Grossman and Roudner, 1980): The
circular plastic measuring device is wrapped around the breast to form a cone, and the
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volume is read off the overlap of the radius with the surface of the cone with the woman
sitting and leaning backward at a 45 degree angle. A larger size was constructed for
volumes of 450-600 cc corresponding to size D, adding to the standard sizes A, B, and C
that come with the set sold commercially in the past.
2. Breast Casting: The woman lay in a semi-recumbant position, and gentle pressure was
applied to the breast to define the margins of the glandular tissue. Rubber cement (like
the glue used to make scrapbooks) was painted at the margins of the glandular tissue to
attach kite string to the skin and mark the breast tissue margins. Strips of plaster of Paris
impregnated gauze (like those used to make splints) were cut to the size of the anterior
thorax, dipped in warm water and applied over the breast, completely covering the
glandular tissue as well as the string.
Three layers of plaster of Paris impregnated gauze were applied and allowed to
harden. The cast of the breast along with the string was lifted from the chest. The string
was then removed, leaving a groove in the Plaster of Paris defining the limits of the
breast on the inner aspects of the cast. After further drying, the inner portion of the cast
was sealed with rubber cement. A 50:50 fine sand and butter mixture was then placed in
the cast and smoothed to the concavity of the chest wall. The volume of the sand-butter
mixture was measured by water displacement in a graduated cylinder.
3. Magnetic Resonance Imaging: The women went for an MRI examination of their
breasts. The MRI machine was made by Siemens and has a 1.5 tesla magnet. The
volume of the breast tissue was determined from the MRI data files in the imaging
laboratory using a procedure for quantifying visceral fat adapted to the quantification of
breast volume. An attempt was made to include only the glandular tissue of the breast in
each measure. The volume of each slice of the breast was determined. The whole breast
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volume was calculated by adding the volumes of the individual slices together. MRI
slices were 8.4 mm apart in the sagittal plane, and volume was calculated using the
ANALYZE bio-imaging software.
Analysis
The mean and standard deviation of the three breast volume measures of the three
methods on each subject were used to construct a power analysis determining the number of
subjects needed to detect a 5% change in breast volume with 80% power and an alpha of 0.05.
The number of subjects was multiplied by the cost of the test to determine the most cost effective
method to use.
Results
Three measurements were made in each of the five subjects with each of the three
measurement methods (Table 3.1). The mean and standard deviation of the mean were
calculated for each subject using each of the three measurement methods. A power analysis was
then performed to determine the number of subjects that would be needed to detect a 5% change
in volume given these variances with 80% power and an alpha of 0.05. The number of subjects
needed to detect a 5% change in each subject for each test was multiplied by the cost of the test
in question. These costs to detect a 5% change in volume for each of the tests were compared
over the range of breast sizes (Table 3.2).
Measuring the breast using the Grossman-Roudner cone takes about ten minutes to
perform for a person getting paid minimum wage. Therefore, volumes with this device cost
about $1.00 per measurement. The casting material is made of gauze impregnated with plaster
of Paris. This measurement takes about one hour to perform the test and about one hour to
measure the volume of the breast for a person getting paid minimum wage, which totals to about
$12.00. The cost of the material used for each measurement, including the gauze impregnated
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with plaster of Paris, kite string, butter, sand, and rubber cement is about $8.00. Therefore,
measurements with this device cost about $20.00 per measurement.
The three MRI scans take about thirty minutes to capture each of the breast images.
Measurements with this device cost about $1,400 for each MRI scan performed.
The ratio of relative costs to detect a 5% change in breast volume for the GrossmanRoudner cone, cast, and MRI is 1:64-189:373-33,500 (1:127:16,967) respectively. Since these
ratio ranges do not overlap, the Grossman-Roudner Breast Measuring Device clearly is the most
cost effective method for determining changes in breast volume in studies testing topical
therapies to change breast size.

Table 3.1. Measurements of Cup Sizes AA, A, B, C, and D
Cup Size

AA

A

B

C

D

Cone (cc)

160

170

290

325

470

Cone (cc)

165

165

300

350

495

Cone (cc)

160

180

280

350

515

Cast (cc)

251

260

435

475

780

Cast (cc)

255

270

430

555

690

Cast (cc)

235

320

365

530

655

MRI (cc)

347.5

465

512

544

940

MRI (cc)

377.3

465

475

556

969

MRI (cc)

440.7

472

484

524

968
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Table 3.2. Relative Number and Cost to Detect a 5% Change in Breast Volume
Cup Size

AA

A

B

C

D

Cone (mean in cc + SD)

162 + 3

171 + 6

290 + 10

342 + 14

493 + 23

N for 5% change

4

10

9

13

15

$ for 5% change

4

10

9

13

15

Cast

247 + 11

283 + 32

405 + 33

539 + 50

708 + 64

N for 5% change

13

82

85

56

54

$ for 5% change

260

1,640

1,700

1,120

1,080

MRI

389 + 48

467 + 4

490 + 19

541 + 16

959 + 16

N for 5% change

96

3

11

7

4

$ for 5% change

134,400

4,200

15,400

9,800

5,600

Discussion
Several methods have been proposed to measure breast volume, but no cost-effectiveness
evaluation comparing methods has been done. Anatomical measures to fit brassieres, water
displacement, casting, the Grossman-Roudner cone, photography, mammograms, ultrasound and
magnetic resonance imaging (MRI) have all been suggested as methods to measure breast
volume.
Anatomical measures such as those used for fitting brassieres are inaccurate for
measuring breast volume due to variability in breast shape (Bulstrode et al., 2001). Cup size is
typically determined by the difference in circumferences of the chest at the submammary crease
and the nipple line. This measure varies considerably as breasts become ptotic. Brassiere sizes
are also inaccurate since cup size varies with each brand.
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Water displacement based on Archimedes principle is another way of determining the
breast volume. The subjects had difficulty performing this test because the breast tissue, being
composed of fat tissue, floated (Bulstrode et al., 2001). The variability of this measurement due
to different levels of submergence was, therefore, common, and the measurement’s wide
variability made it inaccurate (Tezel et al., 2000).
The casting method for determining breast volume has been tested measuring both
breasts at the same time. A study carried out by Campaigne et al. using plaster strips applied
horizontally across both breasts to measure the volume of both breasts gave an error of + 10.2%,
which was due to variability creating the casts and variability filling the casts with sand, resulting
in large within-subject variability (Campaigne et al., 1979). To observe the variability of filling
the casts of the breast pairs with sand, the same person filled 30 randomly selected casts twice,
30 minutes apart. It was estimated that half of the error was due to filling the cast with sand.
Campaigne et al., however, did find that the reproducibility improved after repeating the filling
ten times (1979). In another study analyzing breast volume measurements executed by Bulstrode
et al., thermoplastic sheets were used as the casting material, and only a single breast was
measured (2001). Bulstrode noted that there were no distinguishable disadvantages in using the
casting method to measure breast volume. One had a visual model of the breast to evaluate the
shape, and the thermoplastic molding was a convenient and well-tolerated method for the
subjects. Therefore, we decided to use a casting method for our study to determine breast
volume using a single breast.
The Grossman-Roudner Breast Measuring Device has been developed as an easy,
precise, and cost-effective method of determining breast volume (Grossman et al., 1980). This
method has been compared with the casting method, and the Grossman-Roudner cone proved to
be reproducible (Palin et al., 1986). Jack Grossman, the developer of the Grossman-Roudner
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Breast Measuring Device stated that this method is “simple and direct and by no means absolute
in its volume determination for breasts” (Palin et al., 1986). He further explained that this
technique provides a relative reproducibility that is helpful for aesthetic purposes (Palin et al.,
1986). As a result, we chose to utilize the Grossman-Roudner Breast Measuring Device for our
study to measure breast volume.
Spectrophotography gives the volume measurements and the relative size relationship of
normal breast pairs. We are interested only in breast volume. Costly equipment is necessary for
performing the necessary stereophotogrammetry, and it is a very time-consuming process. In a
study performed by Loughry et al. using this method, wide-angle stereometric cameras, a surface
contrast optical projector, and a double-rail support were required (1987). The stereocameras
were equipped with biogon lenses, vacuum film platens to insure film flatness, and fiber optic
bundles that placed fiducial marks on the exposed film. In addition, the production of the total
breast volumes for the subjects required the use of several mathematical algorithms. A drawback
to using photography as a breast volume measurement is the skill required by the person using
the stereometric cameras, the cost of the associated equipment, and necessary expertise in the
mathematical algorithms.
Mammography, ultrasound, and MRI use similar principles in measuring the volume of
the breast by indirect visualization techniques. Breast volumes determined by mammography
have been demonstrated to have good correlation with breast volumes measured at a subsequent
mastectomy to remove a malignant tumor (Bulstrode et al., 2001). Mammography, however,
involves the risk of radiation exposure that is difficult to justify for cosmetic applications.
Mammography is also more uncomfortable for the subject than the other measurement methods
in this group (Bulstrode et al., 2001). Although ultrasound and MRI use a similar principle to
measure breast volume, the use of magnetic resonance gives much better separation of tissue
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planes and better definition of the breast tissue than the use of ultrasound. Therefore, we chose
to evaluate magnetic resonance as the best measurement to represent this group of methods.
Of the various methods to measure breast volume we selected two anatomic measures
and one indirect measure to evaluate as having the best qualities for cosmetic applications: the
Grossman-Roudner cone, breast casting and magnetic resonance imaging. We expected that the
magnetic resonance imaging would give the most accurate and precise estimation of breast
volume. We expected that the Grossman-Roudner cone would not have sufficient accuracy due
to the device not containing the entire breast tissue within the cone. We expected that the breast
casting would be the most cost-effective measure, since it measured the entire breast and is much
less expensive than magnetic resonance imaging. To our surprise, the Grossman-Roudner cone
was clearly the most cost-effective measure. Despite the fact that the entirety of the breast is not
contained in the cone during measurement, the reproducibility of the measure was comparable to
the magnetic resonance imaging. Therefore, the Grossman-Roudner cone appears to be the most
cost effective and preferred measure for estimating change in breast volume during a cosmetic
treatment program to alter breast size.
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CHAPTER 4
AN EVALUATION OF MESOTHERAPY SOLUTIONS FOR INDUCING LIPOLYSIS
AND TREATING CELLULITE
Background
Michel Pistor gave an intravenous injection of procaine to a man suffering from asthma
in France during the 1950’s, and this experience started the practice of mesotherapy. Although
the asthma did not improve, the man’s long-standing deafness improved temporarily. Dr. Pistor
concluded that injection into the subcutaneous tissues would give the best results, and claimed
many health benefits from his method of injecting procaine locally. Since the tissue into which
he was injecting came from mesodermal origin, he called this technique mesotherapy (Pistor,
1964).
Mesotherapy has gained popularity in France and is now included in French medical
school curricula. Mesotherapy has recently been gaining in popularity in the United States. The
primary application of mesotherapy in the United States has been to induce lipolysis for local fat
reduction and to reduce the appearance of cellulite, the lumpy-bumpy, orange-peel texture of the
skin on the buttocks and thighs of many women. The use of mesotherapy solutions to induce
local lipolysis is primarily based on empirical observations and long-term clinical use, including
the incorporation of local anesthetics like lidocaine or procaine in these mesotherapy solutions.
This study evaluates the lipolytic potential of several compounds commonly used separately and
together in cosmetic mesotherapy solutions using a human fat cell assay with the generation of
glycerol as the measure of lipolysis.
Methods
The lipolysis assay (ZenBio, Research Triangle Park, North Carolina) uses differentiated
human adipocytes, which are adherent to the bottom of each well in a 96 well plate to test the
effects of various compounds on lipolysis. The test compounds will either stimulate or inhibit
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the release of glycerol from the adipocytes relative to the assay buffer, and this difference is
stated as a fold induction index. Controls of assay buffer, saline and positive controls of
isoproterenol and isobutylmethylxanthine (IBMX) were also included. Table 4.1 lists the
mesotherapy solutions tested and the concentrations at which they were tested.
Upon arrival of the lipolysis assay kit, 100 ul of the shipping medium was removed from
each well and discarded. Plate A was placed in the incubator for 5-7 days to allow the cells to
recover from the stress of shipping. Prior to removing Plate A from the incubator, all test
compounds were made by diluting them to their final concentration in Assay Buffer. On the day
of the assay, 150 ul of media was removed from each well of Plate A, and 200 ul of Wash Buffer
was then added to each well of Plate A. Next 200 ul of media and Wash Buffer was removed,
and another 200 ul of Wash Buffer was added to each well of Plate A. All media and Wash
Buffer were removed from each well of Plate A. The cells were treated with 150 ul of the test
compounds and controls, three wells at a time. The diluted IBMX and isoproterenol were treated
as positive controls, and the assay buffer was treated as one of the vehicle controls. The plate
was incubated for five hours at 37 degrees Celsius, 5% CO2.
After incubation, 100ul of the test compounds were removed and added to a sterile 96
well plate. 100ul of glycerol reagent were then added to create a colorimetric assay dependent
on the amount of glycerol released during incubation with the test compounds. A series of
glycerol standards were also run with each assay to create a standard curve upon which the
results were based. The plates were then read in a spectrophotometer plate reader at 540nm and
the results were plotted based on the standard curve.
Results
Isoproterenol, aminophylline, yohimbine (Figure 4.1) and melilotus all significantly
stimulated lipolysis compared to the buffer control. The addition of aminophylline to melilotus
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significantly increased lipolysis compared to melilotus alone (Figure 4.2). The addition of
aminophylline to isoproterenol increased lipolysis significantly compared to isoproterenol alone
(Figure 4.3). The addition of lidocaine to isoproterenol and aminophylline (Figure 4.4) inhibited
lipolysis such that the combination was not statistically different than control. The addition of
lidocaine to the combination of isoproterenol, aminophylline and yohimbine (Figure 4.5)
inhibited lipolysis but the combination was still statistically different than control (p<0.05).

3.5

Glycerol Fold Induction

3
2.5
2
1.5
1
0.5
0

Buffer

Amin

Iso

Yoh

Figure 4.1. Lipolysis Fold Induction Compared to Assay Buffer
Abbreviations: Iso – Isoproterenol, Amin – Aminophylline, Yoh – Yohimbine
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Figure 4.2. Lipolysis Fold Induction Compared to Assay Buffer
Abbreviations: Mel – Melilotus, Amin – Aminophylline
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Figure 4.3. Lipolysis Fold Induction Compared to Assay Buffer
Abbreviations: Iso – Isoproterenol, IA -Isoproterenol, Aminophylline
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Figure 4.4. Lipolysis Fold Induction Compared to Assay Buffer
Abbreviations: IA – Isoproterenol, Aminophylline, IA-L – Isoproterenol, Aminophylline,
and Lidocaine
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Figure 4.5. Lipolysis Fold Induction Compared to Assay Buffer
Abbreviations: IAY – Isoproterenol, Aminophylline, and Yohimbine, IAY-L –
Isoproterenol, Aminophylline, Yohimbine, and Lidocaine

Table 4.1. Stimulation of lipolysis by compounds used in mesotherapy
Components

Concentration

Fold Induction

p-value

IBMX Control

1.0 x 10-4 M

2.3 + 0.24

p<0.01

Assay Buffer

full strength

1.0

Aminophylline

1.0 x 10-4 M

2.5 + 0.57

p<0.00004

Isoproterenol

1.0 x 10-7 M

2.7 + 0.06

p<0.002

Yohimbine

1.0 x 10-7 M

2.0 + 0.19

p<0.001

Melilotus

0.02%

2.2 + 0.33

p<0.01

Melilotus
Aminophylline

0.02%
1.0 x 10-4 M

2.7 + 0.05

p<0.001 vs. control
p<0.001 vs. melilotus
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Table 4.1 Continued
Aminophylline
Isoproterenol

1.0 x 10-4 M
1.0 x 10-7 M

3.6 + 0.42

p<0.001 vs. control
p<0.01vs.Isopro.

Aminophylline
Isoproterenol
Yohimbine

1.0 x 10-4 M
1.0 x 10-7 M
1.0 x 10-7 M

2.5 + 0.12

p<0.0007 vs. control

Aminophylline
Isoproterenol
Lidocaine

1.0 x 10-4 M
1.0 x 10-7 M
1.0 x 10-5 M

1.5 + 0.41

p=NS vs. control

Aminophylline
Isoproterenol
Yohimbine
Lidocaine

1.0 x 10-4 M
1.0 x 10-7 M
1.0 x 10-7 M
1.0 x 10-5 M

1.4 + 0.04

p<0.05 vs. control

Discussion
The most important finding of this study was the inhibition of lipolysis by topical
anesthetics, since almost all mesotherapy solutions have routinely included procaine, lidocaine or
some other topical anesthetic. Evidence, however, exists in the medical literature that local
anesthetics do inhibit lipolysis in human fat cells. Mersmann demonstrated lipolytic inhibition
with procaine (1983), and others have shown that procaine uncouples adenylate cyclase from
activating hormone sensitive lipase, the lipolytic enzyme in fat cells (D’Costa et al., 1979). The
inhibition of lipolysis by procaine is shared by lidocaine (Komabayashi et al., 1978), and since
another topical anesthetic, prilocaine, also inhibits lipolysis, this seems to be a class effect of
local anesthetics (Arner et al., 1973).
Melilotus is an extract of sweet clover that has been used empirically in mesotherapy to
induce lipolysis either alone or in the presence of aminophylline. Our studies confirm that
melilotus used alone stimulates lipolysis and that the addition of aminophylline further increases
lipolysis.
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Isoproterenol, yohimbine and aminophylline are all well recognized lipolytic stimulators
(Greenway et al., 1995). This study just served to confirm that finding. Isoproterenol has been
reported to give fat loss on one thigh using mesotherapy injections compared to saline injections
on the opposite thigh. Although there are no mesotherapy injection studies demonstrating the
clinical efficacy of the other lipolytic stimulators to induce local fat reduction, there are studies
using an ointment containing yohimbine, forskolin and aminophylline, an ointment with
forskolin alone, an ointment with aminophylline alone and a cream with aminophylline alone in
which the treated thigh lost significantly more girth that the thigh treated with placebo
(Greenway et al., 1995 and Greenway and Bray, 1987). This suggests that delivery of lipolytic
agents locally whether by injection or by topical application will cause local fat loss.
Mesotherapists have traditionally combined lipolytic stimulators with the goal of
enhancing lipolysis to a greater extent by the use of polypharmacy. Our studies demonstrate that
lipolysis induced by melilotus is enhanced by aminophylline as is the lipolysis induced by
isoproterenol. Although confirmation will require clinical trials, the enhanced lipolysis in the fat
cell assay suggests that combining lipolytic stimulators will enhance local fat reduction in
mesotherapy practice.
Cellulite is the descriptive name of the lumpy-bumpy, or cottage cheese-appearance that
is apparent on the thighs of some women. This appearance of the fat is felt to be the result of the
connective tissue architecture of subcutaneous fat with women having connective tissue oriented
at right angles to the skins surface as opposed to men who have a more diagonal orientation of
this connective tissue (Pierard et al., 2000). Querleux agrees that women with cellulite have
connective tissue oriented at right angles to the skin surface and describes an increase in the
deeper adipose layer below Camper’s fascia in women with cellulite, but disputes Pierard’s
depiction of the orientation of male connective tissue (Querleux et al., 2002). Since the
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appearance is caused by fat cells bulging against these connective tissue strands, emptying out
these fat cells by stimulating lipolysis will improve the smoothness of the skin surface. This is a
desirable cosmetic effect for many women, and the treatment of cellulite is a major focus of
mesotherapy.
Since injecting isoproterenol in the thighs reduces thigh girth and reduces the appearance
of cellulite, injection of other lipolytic substances should cause local fat reduction and improve
the appearance of cellulite as well. We have confirmed the lipolytic activity of melilotus,
aminophylline, yohimbine and isoproterenol in a human fat cell assay, ingredients which are
used for local fat reduction and to reduce the appearance of cellulite in the practice of
mesotherapy. We have also demonstrated that combinations of these lipolytic stimulators used
in the practice of mesotherapy give greater stimulation of lipolysis than the individual
components alone. Most importantly, we confirmed earlier reports in the literature showing that
lidocaine and other topical anesthetics inhibit lipolysis. We believe that local anesthetics such as
lidocaine and its class derivatives should be removed from mesotherapy solutions designed to
cause local fat reduction and reduce the appearance of cellulite.
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CHAPTER 5
SUMMARY AND CONCLUSIONS
The first study confirmed that aminophylline cream application to the waist will reduce
waist circumference compared to a control. At week twelve, the BMI in the aminophylline
cream group was 26.1 + 1.0 kg/m2 and 26.2 + 1.0 kg/m2 in the control group, a significant
reduction in BMI from baseline of 2 kg/m2 in both groups. The reduction in waist circumference
was 11 + 1.0 cm in the aminophylline cream group and 5.0 + 0.6 cm in the control group
(p<0.001). The reduction in waist circumference was significant for both women (11.6 + 0.6 cm
in the aminophylline group and 5.6 + 0.6 cm in the control group) and men (9.4 + 0.7 cm in the
aminophylline group and 4.7 + 0.6 cm in the control group) (p<0.001). Women treated with
0.5% aminophylline cream lost more girth (11.6 + 0.6 cm vs. 9.4 + 0.7 cm) than the men
(p<0.001). The waist to hip ratio declined more in the group treated with 0.5% aminophylline
cream than the control group (0.08 + 0.03 vs. 0.02 + 0.03, p<0.01). The waist to hip ratio in
women declined more in the group treated with 0.5% aminophylline cream than the control
group (0.12 + 0.001 vs. 0.05 + 0.001, p<0.001), and the waist to hip ratio in men declined more
in the group treated with 0.5% aminophylline cream than the control group, but this difference
was not statistically significant (0.2 + 0.06 vs. 0.09 + 0.07, NS). The lack of difference in weight
loss between the two groups and the difference in waist circumference suggests a cosmetic
change in fat distribution. All monthly aminophylline levels were undetectable. There were no
adverse events or allergic reactions to the cream. Blood pressure and pulse remained in the
normal range throughout the study.
This trial demonstrates that reducing the local lipolytic threshold with topical
aminophylline cream results in a reduction of waist circumference in both men and women.
Local girth reduction of the waist in android body types is consistent with the principle that
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lowering the local lipolytic threshold causes fat reduction in the area of application. Thus, the
principle of local fat reduction with aminophylline cream can be applied to both genders and to a
body area different from the thigh. This difference in waist circumference with a similar weight
loss in the two groups suggests a cosmetic redistribution of body fat.
The second study developed a cost-effective method of breast measurement that will
allow the concept of fat redistribution to be tested. Anatomical measures to fit brassieres, water
displacement, casting, the Grossman-Roudner cone, photography, mammograms, ultrasound, and
MRI have all been suggested as methods to measure breast volume, but no cost-effectiveness
evaluation comparing methods has been done. Breast volume measurements using the
Grossman-Roudner measuring device, plaster casting, and MRI were compared. It was predicted
that the magnetic resonance imaging would give the most accurate and precise estimation of
breast volume since it is the gold standard. It was expected that the Grossman-Roudner cone
would not have sufficient accuracy due to the device not containing the entire breast tissue
within the cone. It was projected that the breast casting would be the most cost-effective
measure, since it measured the entire breast and is much less expensive than magnetic resonance
imaging. Surprisingly, the Grossman-Roudner cone was clearly the most cost-effective measure.
Despite the fact that the entire breast tissue is not contained in the cone during measurement, the
reproducibility of the measure was comparable to the magnetic resonance imaging. Therefore,
the Grossman-Roudner cone appears to be the most cost effective and preferred measure for
estimating change in breast volume during a cosmetic treatment program to alter breast size.
The third study demonstrates that single mesotherapy drugs used in mesotherapy
solutions increase lipolysis, and the combination solutions increase lipolysis greater than the
individual ingredients. This study also shows that lidocaine and other topical anesthetics inhibit
lipolysis of mesotherapy solutions. The following single drugs and herbs were tested and
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elevated lipolysis by the following multiples of the glycerol generation attributable to the assay
buffer: isoproterenol 10-7 M: 2.7 times, aminophylline 10-4 M: 2.5 times, yohimbine 10-7 M:
2.0 times, melilotus extract 0.02%: 2.2 times, but triac, a derivative of thyroid hormone did not
stimulate lipolysis. The following combinations increased glycerol generation by the following
multiples of the assay buffer control: isoproterenol and aminophylline: 3.6 times, isoproterenol,
aminophylline and yohimbine: 2.5 times, melilotus and aminophylline: 2.7 times.
The addition of lidocaine to either of the first two combinations blocked lipolysis.
Lidocaine and procaine both block lipolysis by uncoupling the increase of cyclic-AMP inside the
fat cell from hormone sensitive lipase activation. It is concluded that with the possible exception
of triac, the single mesotherapy drugs or homeopathic ingredients used in mesotherapy solutions
that we tested increase lipolysis. Combination mesotherapy solutions increase lipolysis more
than the individual ingredients. Lidocaine and other local anesthetics should be removed from
mesotherapy solutions because they block lipolysis.
These studies set the stage for our future research. We have demonstrated that
mesotherapy is an effective method for proof of concept studies to redistribute local fat deposits
for cosmetic purposes. Studies to test the safety of different potential mesotherapy solutions in
animals are planned in preparation for future human studies. Since we have shown that topical
cream application will cause fat loss locally for cosmetic purposes, our next goal is to
demonstrate that fat can be shifted from the hip and thighs to the breasts. In preparation for these
studies, we have validated a cost-effective method of breast measurement. Thus, the studies in
this thesis set the stage for a new chapter in cosmetic therapy, creams that will allow body
sculpturing with fat augmentation and fat loss in different body areas. Not only does this offer
the potential for improvements in quality of life, but it may also reduce the need for more risky
and invasive plastic surgical procedures, thereby producing a public health benefit as well.
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